Growth differentiation factor-15 as an emerging biomarker for identifying myositis

References

• Amato AA, Greenberg SA. Inflammatory myopathies. Continuum (Minneap Minn). 2013;19:1615–1633.
   PubMedGoogle Scholar
• Lundberg IE, Tjärnlund A, Bottai M, et al. EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76:1955–1964.
   PubMed Web of Science ®Google Scholar
• Leclair V, Lundberg IE. New myositis classification criteria—what we have learned since Bohan and Peter. Curr Rheumatol Rep. 2018;20:e18.
   PubMed Web of Science ®Google Scholar
• Oldroyd A, Chinoy H. Recent developments in classification criteria and diagnosis guidelines for idiopathic inflammatory myopathies. Curr Opin Rheumatol. 2018;30:606–613.
   PubMed Web of Science ®Google Scholar
• Fer F, Allenbach Y, Benveniste O. Myositis: from classification to diagnosis. Rev Med Interne. 2021;42:392–400.
   PubMed Web of Science ®Google Scholar
• Mariampillai K, Granger B, Amelin D, et al. Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies. JAMA Neurol. 2018;75:1528–1537.
   PubMed Web of Science ®Google Scholar
• Schmidt J. Current classification and management of inflammatory myopathies. J Neuromuscul Dis. 2018;5:109–129.
   PubMedGoogle Scholar
• Dani L, Che WI, Lundberg IE, et al. Overall and site-specific cancer before and after diagnosis of idiopathic inflammatory myopathies: a nationwide study 2002-2016. Sem Arthr Rheum. 2020;51:331–337.
   PubMed Web of Science ®Google Scholar
• De Paepe B, De Bleecker JL. Chapter 5. The heterogeneity of immune-mediated necrotizing myopathy illustrated in a cohort of Belgian patients: consequences for diagnosis and disease management. In: Lt D, editor. Advances in health and disease. Vol. 39, New York (NY): Nova Biomedical; 2021. p. 121–163.
   Google Scholar
• Pinal-Fernandez I, Casal-Dominguez H, Mammen AL. Immune-mediated necrotizing myopathy. Curr Rheumatol Rep. 2018;20:e21.
   PubMed Web of Science ®Google Scholar
• Allenbach Y, Mammen AL, Benveniste O, et al. Immune-Mediated Necrotizing Myopathies Working Group 224th ENMC International Workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016. Neuromuscul Disord. 2018;28:87–99.
   PubMed Web of Science ®Google Scholar
• Lim J, Rietveld A, De Bleecker JL, et al. Seronegative patients form a distinctive subgroup of immune-mediated necrotizing myopathy. Neurol Neuroimmunol Neuroinflamm. 2019;6:e513.
   PubMed Web of Science ®Google Scholar
• Milone M. Diagnosis and management of immune-mediated myopathies. Mayo Clin Proc. 2017;92:826–837.
   PubMed Web of Science ®Google Scholar
• Waldman R, DeWane ME, Lu J. Dermatomyositis: diagnosis and treatment. J Am Acad Dermatol. 2020;82:283–296.
   PubMed Web of Science ®Google Scholar
• Masiak A, Kulczycka J, Czuszyńska Z, et al. Clinical characteristics of patients with anti-TIF1-γ antibodies. Reumatologia. 2016;54:14–18.
   PubMedGoogle Scholar
• Allenbach Y, Uzunhan Y, Toquet S, et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases. Neurology. 2020;95:e70–8.
   PubMed Web of Science ®Google Scholar
• Okogbaa J, Batiste L. Dermatomyositis: an acute flare and current treatments. Clin Med Insights Case Rep. 2019;12:1179547619855370.
   Web of Science ®Google Scholar
• Askanas V, Engel WK, Nogalska A. Pathogenic considerations in sporadic inclusion-body myositis, a degenerative muscle disease associated with aging and abnormalities of myoproteostasis. J Neuropath Exp Neurol. 2012;71:680–693.
   PubMed Web of Science ®Google Scholar
• Amlani A, Choi MY, Tarnopolsky M, et al. Anti-NT5c1A Autoantibodies as biomarkers in inclusion body myositis. Front Immunol. 2019;10:e745.
   PubMed Web of Science ®Google Scholar
• Bottai M, Tjärnlund A, Santoni G, et al. UK and Ireland EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open. 2017;3:e000507.
   PubMed Web of Science ®Google Scholar
• Witt LJ, Curran JJ, Strek ME. The diagnosis and treatment of antisynthetase syndrome. Clin Pulm Med. 2016;23:218–226.
   PubMedGoogle Scholar
• De Paepe B, Creus KK, De Bleecker JL. Role of cytokines and chemokines in idiopathic inflammatory myopathies. Curr Opin Rheumatol. 2009;21:610–616.
   PubMed Web of Science ®Google Scholar
• Johann K, Kleinert M, Klaus S. The role of GDF15 as a myokine. Cells. 2021;10:e2990.
   PubMedGoogle Scholar
• Breit SN, Brown DA, Wang-Wei Tsai V. The GDF15-GFRAL pathway in health and metabolic disease: friend or foe?. Annu Rev Physiol. 2021;83:127–151.
   PubMed Web of Science ®Google Scholar
• Rochette L, Zeller M, Cottin Y, et al. Insights into mechanisms of GDF15 and receptor GFRAL: therapeutic targets. Trends Endocrinol Metab. 2020;31:939–951.
   PubMed Web of Science ®Google Scholar
• Macia L, Wang-Wei Tsai V, Nguyen AD, et al. Macrophage inhibitory cytokine 1 (MIC-1/GDF15) decreases food intake, body weight and improves glucose tolerance in mice on normal & obesogenic diets. PLoS One. 2012;7:e34868.
   PubMed Web of Science ®Google Scholar
• Mullican SE, Lin-Schmidt X, Chin CN, et al. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nat Med. 2017;23:1150–1157.
   PubMed Web of Science ®Google Scholar
• Yang L, Chang CC, Sun Z, et al. GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand. Nat Med. 2017;23:1158–1166.
   PubMed Web of Science ®Google Scholar
• Desmedt S, Desmedt V, De Vos L, et al. Growth differentiation factor 15: a novel biomarker with high clinical potential. Crit Rev Clin Lab Sci. 2019;56:333–350.
   PubMed Web of Science ®Google Scholar
• Bloch SAA, Lee JY, Syburra T, et al. Increased expression of GDF-15 may mediate ICU-acquired weakness by down-regulating muscle microRNAs. Thorax. 2015;70:219–228.
   PubMed Web of Science ®Google Scholar
• Kalko SG, Paco S, Jou C, et al. Transcriptomic profiling of TK2 deficient human skeletal muscle suggests a role for the p53 signalling pathway and identifies growth and differentiation factor-15 as a potential novel biomarker for mitochondrial myopathies. BMC Genomics. 2014;15:e91.
   PubMed Web of Science ®Google Scholar
• Garfield AC, Shao D, Yang P, et al. Growth/differentiation factor 15 causes TGFβ-activated kinase 1-dependent muscle atrophy in pulmonary arterial hypertension. Thorax. 2018;0:1–13.
   Google Scholar
• Patel MS, Lee J, Baz M, et al. Growth differentiation factor-15 is associated with muscle mass in chronic obstructive pulmonary disease and promotes muscle wasting in vivo. J Cach Sarc Muscle. 2016;7:436–448.
   PubMed Web of Science ®Google Scholar
• Neto N, Di Lazzaro L, Seelaender M, et al. Circulating levels of GDF-15, a putative mediator of cachexia, are increased in cancer patients independently of weight loss. Clin Nutr. 2018;37:S183.
   Google Scholar
• Peloquin M, LaCarubba B, Joaqium S, et al. Growth differentiation factor 15 (GDF-15) inhibition to increase muscle mass and function in cancer cachexia. J Clin Oncol. 2020;38:e15633.
   Web of Science ®Google Scholar
• Ahmed DS, Isnard S, Lin J, et al. GDF15/GFRAL pathway as a metabolic signature for cachexia in patients with cancer. J Cancer. 2021;12:1125–1132.
   PubMed Web of Science ®Google Scholar
• Xie Y, Liu S, Zheng H, et al. Utility of plasma GDF-15 for diagnosis and prognosis assessment of ICU-acquired weakness in mechanically ventilated patients: prospective observational study. BioMed Res Int. 2020;2020:e3630568. https://doi.org/https://doi.org/10.1155/2020/3630568
   PubMed Web of Science ®Google Scholar
• Semba RD, Gonzalez-Freire M, Tanaka T, et al. Elevated plasma growth and differentiation factor 15 is associated with slower gait speed and lower physical performance in healthy community-dwelling adults. J Gerontol A Biol Sci Med Sci. 2020;75:175–180.
   PubMed Web of Science ®Google Scholar
• Herpich C, Franz K, Ost M, et al. Associations between serum GDF15 concentrations, muscle mass, and strength show sex-specific differences in older hospital patients. Rejuvenation Res. 2020;24:14–19.
   PubMed Web of Science ®Google Scholar
• Nga HT, Jang IY, Kim DA, et al. Serum GDF15 level is independent of sarcopenia in older Asian adults. Gerontology. 2021;Online ahead of print. DOI:https://doi.org/10.1159/000513600.
   Google Scholar
• De Paepe B, Verhamme F, De Bleecker JL. The myokine GDF-15 is a potential biomarker for myositis and associates with the protein aggregates of sporadic inclusion body myositis. Cytokine. 2020;127:e154966.
   PubMed Web of Science ®Google Scholar
• Oikawa Y, Izumi R, Koide M, et al. Mitochondrial dysfunction underlying sporadic inclusion body myositis is ameliorated by the mitochondrial homing drug MA-5. PLoS One. 2020;15:e0231064.
   PubMed Web of Science ®Google Scholar
• Davis RL, Liang C, Sue CM. A comparison of current serum biomarkers as diagnostic indicators of mitochondrial diseases. Neurology. 2016;86:2010–2015.
   PubMed Web of Science ®Google Scholar
• Yatsuga S, Fujita Y, Ishii A, et al. Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders. Ann Neurol. 2015;78:814–823.
   PubMed Web of Science ®Google Scholar
• Catalán-García M, García-García FJ, Moreno-Lozano PJ, et al. Mitochondrial dysfunction: a common hallmark underlying comorbidity between sIBM and other degenerative and age-related diseases. J Clin Med. 2020;9:e1446.
   PubMed Web of Science ®Google Scholar
• De Paepe B. Sporadic inclusion body myositis: an acquired mitochondrial disease with extras. Biomolecules. 2019;9:e15.
   PubMed Web of Science ®Google Scholar
• Fujita Y, Taniguchi Y, Shinkai S, et al. Secreted growth differentiation factor 15 as a potential biomarker for mitochondrial dysfunctions in aging and age-related disorders. Geriatr Gerontol Int. 2016;16:17–29.
   PubMed Web of Science ®Google Scholar
• Qui M, Sun X, Qi X, et al. The diagnostic value of GDF-15 for myocardial involvement in idiopathic inflammatory myopathy. Rheumatology. 2021;60:2826–2833.
   PubMed Web of Science ®Google Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344–347.
   PubMed Web of Science ®Google Scholar
• Alhatou MI, Sladky JT, Bagasra O, et al. Mitochondrial abnormalities in dermatomyositis: characteristic pattern of neuropathology. J Mol Histol. 2004;35:615–619.
   PubMed Web of Science ®Google Scholar
• Lockhart SM, Saudek V, O’Rahilly S. GDF15: a hormone conveying somatic distress to the brain. Endocr Rev. 2020;41:610–642.
   Web of Science ®Google Scholar
• Conte M, Martucci M, Mosconi G, et al. GDF15 plasma level is inversely associated with level of physical activity and correlates with markers of inflammation and muscle weakness. Front Immunol. 2020;11:e915.
   PubMed Web of Science ®Google Scholar
• Campderrós L, Sánchez-Infantes D, Villarroya J, et al. Altered GDF15 and FGF21 Levels in response to strenuous exercise: a study in marathon runners. Front Physiol. 2020;11:e550102.
   PubMed Web of Science ®Google Scholar
• Dimitri D, Eymard B. Inflammatory myopathies, autoimmune necrotizing myopathies and adult-onset genetic myopathies: differential diagnosis. Rev Med Interne. 2011;33:134–142.
   PubMed Web of Science ®Google Scholar
• Rosenberg AS, Puig M, Nagaraju K, et al. Immune-mediated pathology in Duchenne muscular dystrophy. Sci Transl Med. 2015;7:299rv4.
   PubMed Web of Science ®Google Scholar
• Serra F, Quarta M, Canato M, et al. Inflammation in muscular dystrophy and the beneficial effects of non-steroidal anti-inflammatory drugs. Muscle Nerve. 2012;46:773–784.
   PubMed Web of Science ®Google Scholar
• Straub V, Murphy A, Udd B, et al. 229th ENMC international workshop: limb girdle muscular dystrophies nomenclature and reformed classification Naarden, the Netherlands,17–19 March. Neuromuscul Disord. 2017;28:702–710.
   Web of Science ®Google Scholar
• Montero R, Yubero D, Villarroya J, et al. GDF-15 Is elevated in children with mitochondrial diseases and is induced by mitochondrial dysfunction. PLoS One. 2016;11:e0148709.
   PubMed Web of Science ®Google Scholar
• Tsygankova PG, Itkis YS, Krylova TD, et al. Plasma FGF-21 and GDF-15 are elevated in different inherited metabolic diseases and are not diagnostic for mitochondrial disorders. J Inherit Metab Dis. 2019;42:918–933.
   PubMed Web of Science ®Google Scholar
• Scharff Poulsen N, Lindhardt Madsen K, Munkeboe Hornsyld T, et al. Growth and differentiation factor 15 as a biomarker for mitochondrial myopathy. Mitochondrion. 2020;50:35–41.
   PubMed Web of Science ®Google Scholar
• Peñas A, Fernández-de La Torre M, Laine-Menéndez S, et al. Plasma gelsolin reinforces the diagnostic value of FGF-21 and GDF-15 for mitochondrial disorders. Int J Mol Sci. 2021;22:e6396.
   PubMed Web of Science ®Google Scholar
• Gramegna LL, Giannoccaro MP, Manners DN, et al. Mitochondrial dysfunction in myotonic dystrophy type 1. Neuromuscul Disord. 2018;28:144–149.
   PubMed Web of Science ®Google Scholar
• Lovadi E, Csereklyei M, Merkli H, et al. Elevated FGF 21 in myotonic dystrophy type 1 and mitochondrial diseases. Muscle Nerve. 2017;55:564–569.
   PubMed Web of Science ®Google Scholar
• McHugh NJ, Tansley SL. Autoantibodies in myositis. Nat Rev Rheumatol. 2018;14:290–302.
   PubMed Web of Science ®Google Scholar
• Satoh M, Tanaka S, Ceribelli A, et al. A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol. 2017;52:1–19.
   PubMed Web of Science ®Google Scholar
• Cerezo LA, Vencovský J, Ladislava S. Cytokines and inflammatory mediators as promising markers of polymyositis/dermatomyositis. Curr Opin Rheumatol. 2020;32:534–541.
   PubMed Web of Science ®Google Scholar
• Grundtman C, Malmström V, Lundberg IE. Immune mechanisms in the pathogenesis of idiopathic inflammatory myopathies. Arthritis Res Ther. 2007;9:e208.
   PubMed Web of Science ®Google Scholar
• Mageriu V, Manole E, Bastian AE, et al. Role of myokines in myositis pathogenesis and their potential to be new therapeutic targets in idiopathic inflammatory myopathies. J Immunol Res. 2020;2020:9079083.
   PubMed Web of Science ®Google Scholar
• Gono T, Kaneko H, Kawaguchi Y, et al. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology. 2014;53:2196–2203.
   PubMed Web of Science ®Google Scholar
• Chen M, Quan C, Diao L, et al. Measurement of cytokines and chemokines and association with clinical severity of dermatomyositis and clinically amyopathic dermatomyositis. Transl Res. 2018;179:1334–1341.
   Google Scholar
• Tawalbeh SM, Marin W, Morgan GA, et al. Serum protein biomarkers for juvenile dermatomyositis: a pilot study. BMC Rheumatol. 2020;4:e52.
   PubMedGoogle Scholar
• Uruha A, Noguchi S, Sato W, et al. Plasma IP-10 level distinguishes inflammatory myopathy. Neurology. 2015;85:293–294.
   PubMedGoogle Scholar
• Wu CY, Li L, Zhang LH. Detection of serum MCP-1 and TGF-β1 in polymyositis/dermatomyositis patients and its significance. Eur J Med Res. 2019;24:e12.
   PubMed Web of Science ®Google Scholar
• Muro Y, Sugiura K, Akiyama M. Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Clin Rheumatol. 2013;32:395–398.
   PubMed Web of Science ®Google Scholar
• Oda K, Kotani T, Takeuchi T, et al. Chemokine profiles of interstitial pneumonia in patients with dermatomyositis: a case control study. Sci Rep. 2017;7:e1635.
   PubMed Web of Science ®Google Scholar
• Lehtonen JM, Auranen M, Darin N, et al. Diagnostic value of serum biomarkers FGF21 and GDF15 compared to muscle sample in mitochondrial disease. J Inherit Metab Dis. 2020;44:469–480.
   PubMed Web of Science ®Google Scholar
• Benveniste O, Goebel HH, Stenzel W. Biomarkers in inflammatory myopathies—an expanded definition. Front Neurol. 2019;10:e554.
   PubMed Web of Science ®Google Scholar
• Aleksza M, Szegedi A, Antal-Szalmás P, et al. Altered cytokine expression of peripheral blood lymphocytes in polymyositis and dermatomyositis. Ann Rheum Dis. 2003;64:1485–1489.
   Web of Science ®Google Scholar
• Maeda M. Serum cytokine analysis in idiopathic inflammatory myopathies diagnosed on the basis of pathological findings. Neurology. 2014;82:3.301.
   Google Scholar
• Khazaei Asl S, Shahraki A, Zakeri Z. Investigation on serum levels of Interleukin-18 and Interleukin-6 in patients with dermatomyositis and polymyositis. Shiraz E-Med J. 2016;17:e34981.
   Google Scholar
• Moon JS, Goeminne LJE, Kim JT, et al. Growth differentiation factor 15 protects against the aging-mediated systemic inflammatory response in humans and mice. Aging Cell. 2020;19:e13195.
   PubMed Web of Science ®Google Scholar
• Oba K, Ishikawa J, Tamura Y, et al. Serum growth differentiation factor 15 level is associated with muscle strength and lower extremity function in older patients with cardiometabolic disease. Geriatr Gerontol. 2020;20:980–987.
   PubMed Web of Science ®Google Scholar